Skip to main content
Kyle LaHucik on Muck Rack

Kyle LaHucik

Verified
Chicago
As seen in: Endpoints News, Bloomberg News, Forbes, Los Angeles Times, Yahoo Finance, Stuff.co.nz, Substack, Chron, Detroit News, Financial Post, Bangor Daily News and
reporting on the $, people & startups in biotech for @Endpts | klahucik@endpoints.news | askin Qs, joggin 26.2 | 📷 🌎 | high school XC + Track coach | 🏳️‍🌈
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Kyle

Contact Kyle, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

In latest deal, Innovent seeds Spero's future beyond GSK-owned antibiotic

|
By Kyle LaHucik Verified
| Endpoints News Verified
In latest deal, Innovent seeds Spero's future beyond GSK-owned antibiotic After partnering with four of the largest pharmaceutical companies over the past 18 months, Innovent Biologics is turning to a smaller partner for its next … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Open in Who Shared Issue with article?

After $4.7B sale to Novo Nordisk, former Akero team announces new I&I company with China drug

|
By Kyle LaHucik Verified
| Endpoints News Verified
Used by LinkedIn for probabilistic matching of user identity for ad targeting and analytics reporting. Set by LinkedIn to store a unique browser identifier used for authentication and ad analytics. Set by LinkedIn for data centre routing optimisation. Used to select the appropriate server for handling user requests. Set by LinkedIn to sync ad targeting IDs across services. Used for building audience segments for remarketing.
Open in Who Shared View Duplicates (9) Issue with article?

Apnimed files for IPO as FDA reviews its sleep apnea drug

|
By Kyle LaHucik Verified
| Endpoints News Verified
Apnimed files for IPO as FDA reviews its sleep apnea drug Apnimed is finally going forward with an IPO attempt after years of flirting with the milestone. The Cambridge, MA-based biotech revealed its Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Open in Who Shared Issue with article?
See all 2,999 licensed articles (3,185 Total)